Akero Therapeutics (NASDAQ:AKRO) COO Jonathan Young Sells 12,500 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 12,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $47.76, for a total transaction of $597,000.00. Following the completion of the sale, the chief operating officer owned 196,898 shares in the company, valued at $9,403,848.48. This represents a 5.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Jonathan Young also recently made the following trade(s):

• On Thursday, September 11th, Jonathan Young sold 586 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.02, for a total transaction of $25,209.72.
• On Tuesday, September 2nd, Jonathan Young sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $46.08, for a total transaction of $576,000.00.
• On Tuesday, August 12th, Jonathan Young sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $47.79, for a total transaction of $597,375.00.

Akero Therapeutics Stock Down 0.7%

Shares of AKRO stock opened at $46.10 on Friday. The company has a market capitalization of $3.69 billion, a price-to-earnings ratio of -23.05 and a beta of -0.29. Akero Therapeutics, Inc. has a one year low of $21.34 and a one year high of $58.40. The company’s fifty day moving average price is $47.05 and its 200-day moving average price is $46.63. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.66 and a quick ratio of 12.66.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, August 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.11. During the same quarter in the prior year, the company earned ($0.81) earnings per share. Sell-side analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AKRO. TD Cowen began coverage on shares of Akero Therapeutics in a research report on Monday, August 4th. They issued a “buy” rating and a $76.00 price objective for the company. Cowen initiated coverage on shares of Akero Therapeutics in a research report on Monday, August 4th. They issued a “buy” rating for the company. HC Wainwright assumed coverage on shares of Akero Therapeutics in a research note on Thursday, September 4th. They set a “buy” rating and a $72.00 price objective for the company. Wall Street Zen upgraded shares of Akero Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Akero Therapeutics in a research note on Saturday, September 27th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.14.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC acquired a new position in Akero Therapeutics during the 2nd quarter valued at approximately $3,925,000. Hudson Bay Capital Management LP boosted its holdings in shares of Akero Therapeutics by 28.0% in the 2nd quarter. Hudson Bay Capital Management LP now owns 386,523 shares of the company’s stock valued at $20,625,000 after acquiring an additional 84,573 shares during the last quarter. Headlands Technologies LLC boosted its holdings in shares of Akero Therapeutics by 6,783.5% in the 2nd quarter. Headlands Technologies LLC now owns 8,329 shares of the company’s stock valued at $444,000 after acquiring an additional 8,208 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Akero Therapeutics by 54.1% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 6,242 shares of the company’s stock valued at $334,000 after acquiring an additional 2,192 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Akero Therapeutics by 1,018.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 18,369 shares of the company’s stock valued at $980,000 after acquiring an additional 16,727 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.